Novo Nordisk is suspended from ABPI membership

Novo Nordisk, the Danish multinational pharmaceutical company, has been suspended from the Association of the British Pharmaceutical Industry (ABPI) for two years following serious breaches of the ABPI Code of Practice. As a result, the company will not be able to access the benefits of ABPI membership until it demonstrates a return to industry compliance standards.